Literature DB >> 2848533

Unique presynaptic alpha 2-receptor selectivity and specificity of the antihypertensive agent moxonidine.

B I Armah1.   

Abstract

The characteristics of the alpha-receptor activating property of the new antihypertensive agent moxonidine (4-chloro-N-(4, 5-dihydro-1H-imidazol-2-yl)-6-methyl-2-methyl-5-pyrimidinamine, BDF 5895) was studied using peripheral vasculature and brain membranes of various animals. Moxonidine exerted a full agonist effect in elevating diastolic blood pressure in the pithed rat. Activation of postsynaptic alpha 1- and alpha 2-receptors contribute to the vasoconstrictory effect in rats. In the vasculature of the rabbit, moxonidine was a full agonist at presynaptic alpha 2-receptors in inhibiting transmitter release induced by electrical stimulation of pulmonary artery strips. At postsynaptic sites, exogenously applied moxonidine was a full agonist at alpha 1-receptors in the isolated aorta, pulmonary artery and vena cava of the rabbit. Selectivity for alpha 2-receptors in the pulmonary artery was 106-fold. In rat brain membranes, moxonidine showed 288-fold greater selectivity for alpha 2-receptors, when the displacement of [3H]-rauwolscine was compared with the displacement of [3H]-prazosin. On the whole, clonidine exhibited greater potency than moxonidine on both alpha-receptor subtypes, but moxonidine consistently showed greater alpha 2-receptor selectivity than clonidine. In the guinea pig myocardium, moxonidine caused neither bradycardia nor tachycardia in the isolated right atrium and produced a negligible positive inotropic effect at 100 mumol/l in the isolated papillary muscle.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2848533

Source DB:  PubMed          Journal:  Arzneimittelforschung        ISSN: 0004-4172


  13 in total

1.  Lack of pharmacokinetic interaction between moxonidine and hydrochlorothiazide.

Authors:  H J Weimann; G Pabst; W Weber
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

2.  Lack of pharmacokinetic interactions between moxonidine and digoxin.

Authors:  G Pabst; H J Weimann; W Weber
Journal:  Clin Pharmacokinet       Date:  1992-12       Impact factor: 6.447

3.  Pharmacological characterization of the imidazoline receptor which mediates inhibition of noradrenaline release in the rabbit pulmonary artery.

Authors:  G J Molderings; F Hentrich; M Göthert
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1991-12       Impact factor: 3.000

4.  Centrally acting imidazolines stimulate vascular alpha 1A-adrenergic receptors in Rat-Tail Artery.

Authors:  Wentsworth B Kennedy; Louis Crane; Ramon R Gonzalez; Oommen K George; Lincoln P Edwards
Journal:  Cell Mol Neurobiol       Date:  2006-08-02       Impact factor: 5.046

5.  Hemodynamic and neurohumoral effects of moxonidine in patients with essential hypertension.

Authors:  V Mitrovic; W Patyna; J Hüting; M Schlepper
Journal:  Cardiovasc Drugs Ther       Date:  1991-12       Impact factor: 3.727

6.  Steady state investigation of possible pharmacokinetic interactions of moxonidine and glibenclamide.

Authors:  M Müller; H J Weimann; G Eden; W Weber; K Michaelis; C Dilger; G Achtert
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1993 Jul-Sep       Impact factor: 2.441

7.  In vivo microdialysis of noradrenaline overflow: effects of alpha-adrenoceptor agonists and antagonists measured by cumulative concentration-response curves.

Authors:  M J van Veldhuizen; M G Feenstra; R P Heinsbroek; G J Boer
Journal:  Br J Pharmacol       Date:  1993-07       Impact factor: 8.739

8.  Relevance of the use of [3H]-clonidine to identify imidazoline receptors in the rabbit brainstem.

Authors:  G Bricca; J Zhang; H Greney; M Dontenwill; J Stutzmann; A Belcourt; P Bousquet
Journal:  Br J Pharmacol       Date:  1993-12       Impact factor: 8.739

Review 9.  Moxonidine. A review of its pharmacology, and therapeutic use in essential hypertension.

Authors:  P Chrisp; D Faulds
Journal:  Drugs       Date:  1992-12       Impact factor: 9.546

10.  Influence of food on the oral bioavailability of moxonidine.

Authors:  R A Theodor; H J Weimann; W Weber; M Müller; K Michaelis
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1992 Jan-Mar       Impact factor: 2.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.